BIODYNE Co., Ltd.

BIODYNE Co., Ltd.

KKRX:314930
5,220.00
KRW
+30.00
(+0.58%)
-9.05EPS
265.29BMarket Cap
Nov 18Next Earn

Total Valuation

KRW

As of June 30, 2026, BIODYNE Co., Ltd. carries a market capitalization of 265.29B, placing it among publicly traded companies globally. Its enterprise value stands at 250.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap265.29B
Enterprise Value250.54B

Important Dates

BIODYNE Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

Earnings Date11/18/2026

Share Statistics

As of June 30, 2026, BIODYNE Co., Ltd. has 29.48M shares outstanding.

Shares Outstanding29.48M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 62.65, and the price-to-book ratio stands at 6.03.

PS Ratio62.65
PB Ratio6.03
P/TBV Ratio6.68
P/FCF Ratio-102.68
P/OCF Ratio-238.55

Enterprise Valuation

As of June 30, 2026, BIODYNE Co., Ltd. trades at an EV/EBITDA multiple of 5,331.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 61.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 250.54B versus a market cap of 265.29B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales61.03
EV / EBITDA5,331.36

Financial Position

As of June 30, 2026, BIODYNE Co., Ltd. maintains a current ratio of 45.95, meaning it holds 46.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.01, indicating conservative leverage, while an interest coverage ratio of 244.76 demonstrates strong ability to service its debt obligations.

Current Ratio45.95
Quick Ratio38.92
Debt / Equity0.01
Debt / EBITDA0.13
Interest Coverage244.76

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, BIODYNE Co., Ltd. posted a negative return on equity (ROE) of -0.60, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.59, reflecting losses generated across the asset base. The company generates approximately 200.26M in revenue per employee across its workforce of 20.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.20 indicates how many times BIODYNE Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.60
Return on Assets (ROA)-0.59
Revenue Per Employee200.26M
Employee Count20.50
Inventory Turnover3.20

Taxes

KRW

Over the twelve months ended June 30, 2026, BIODYNE Co., Ltd. recorded an income tax benefit of -89.52M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -348.20M and -258.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-89.52M

Stock Price Statistics

KRW

As of the close on November 17, 2026, BIODYNE Co., Ltd.'s stock has declined approximately 62.26% over the past 52 weeks. The 50-day moving average sits at 6,294.20, while the 200-day moving average is 9,630.60.

52-Week Price Change-62.26%
50-Day Moving Average6,294.20
200-Day Moving Average9,630.60

Income Statement

KRW

Over the twelve months ended June 30, 2026, BIODYNE Co., Ltd. generated 4.11B in revenue and converted that into -258.68M in net income, yielding earnings per share of -9.05. EBITDA reached 46.99M, while operating income came in at -1.17B.

Revenue4.11B
Gross Profit2.47B
Operating Income-1.17B
Pretax Income-348.20M
Net Income-258.68M
EBITDA46.99M
EBIT-1.17B
Earnings Per Share (EPS)-9.05

Balance Sheet

KRW

As of June 30, 2026, BIODYNE Co., Ltd. holds 14.75B in cash and equivalents against 6.33M in total debt, resulting in a net debt position of -11.75B. Total book value stands at 44.00B, with working capital of 17.04B providing operational flexibility.

Cash & Cash Equivalents14.75B
Total Debt6.33M
Net Debt-11.75B
Equity (Book Value)44.00B
Book Value Per Share1,492.79
Working Capital17.04B

Cash Flow

KRW

BIODYNE Co., Ltd. produced -1.08B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.43B in capital expenditures, free cash flow totaled -2.50B - equivalent to -87.65 per share.

Operating Cash Flow-1.08B
Capital Expenditures-1.43B
Free Cash Flow-2.50B
FCF Per Share-87.65

Margins

Over the twelve months ended June 30, 2026, BIODYNE Co., Ltd. posted a gross margin of 60.16, reflecting its pricing power and cost economics. The operating margin of -28.45 and net profit margin of -6.30 provide insight into operational efficiency.

Gross Margin60.16
Operating Margin-28.45
Pretax Margin-8.48
Profit Margin-6.30
EBITDA Margin1.14

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.97: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.00, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BIODYNE Co., Ltd. shareholders.

FCF Yield-0.97

Stock Splits

BIODYNE Co., Ltd.'s most recent stock split took place on February 28, 2024 with a 1:5 split ratio.

Last Split Date2/28/2024
Split Ratio1:5

Scores

As of June 30, 2026, BIODYNE Co., Ltd. has an Altman Z-Score of 420.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score420.64